Frontier Medicines is leveraging a chemoproteomics platform to try to build a better KRAS G12C

blonca9
Mar 5, 2024
1 min read

Chris Varma describes why hitting KRAS G12C in both its on and off state could be an improvement over existing medicines. He also describes Frontier's platform and a recent $80M series C raise.

Recent Posts

See All

Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs

ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk

ASGCT 2025: Dyno Therapeutics' CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions

Frontier Medicines is leveraging a chemoproteomics platform to try to build a better KRAS G12C

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight